BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance.

Article Details

Citation
Copy to clipboard

Sullivan RJ, Flaherty KT

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance.

J Skin Cancer. 2011;2011:423239. doi: 10.1155/2011/423239. Epub 2011 Nov 17.

PubMed ID
22175026 [ View in PubMed
]
Abstract

Since the initial discovery that a subset of patients with cutaneous melanoma harbor BRAF mutations, substantial research has been focused on determining the pathologic consequences of BRAF mutations, optimizing diagnostic techniques to identify these mutations, and developing therapeutic interventions to inhibit the function of this target in mutation-bearing tumors. Recently, advances have been made which are revolutionizing the standard of care for patients with BRAF mutant melanoma. This paper provides an overview on the pathogenic ramifications of mutant BRAF signaling, the latest molecular testing methods to detect BRAF mutations, and the most recent clinical data of BRAF pathway inhibitors in patients with melanoma and BRAF mutations. Finally, emerging mechanisms of resistance to BRAF inhibitors and ways of overcoming this resistance are discussed.

DrugBank Data that Cites this Article

Drugs